MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%

Ambu A/S

Healthcare US AMBBY

18.78USD
-(-%)

Last update at 2024-10-29T20:00:00Z

Day Range

18.7818.78
LowHigh

52 Week Range

9.4516.85
LowHigh

Fundamentals

  • Previous Close 18.78
  • Market Cap4130.66M
  • Volume1000
  • P/E Ratio170.00
  • Dividend Yield0.32%
  • EBITDA426.00M
  • Revenue TTM4775.00M
  • Revenue Per Share TTM18.33
  • Gross Profit TTM 2554.00M
  • Diluted EPS TTM0.09

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax 210.00M 109.00M 308.00M 322.00M 413.00M
Minority interest - - - - -
Net income 168.00M 93.00M 247.00M 241.00M 317.00M
Selling general administrative 594.00M 517.00M 470.00M 399.00M 292.00M
Selling and marketing expenses 1522.00M 1634.00M 1468.00M 1228.00M 762.00M
Gross profit 2713.00M 2554.00M 2503.00M 2212.00M 1637.00M
Reconciled depreciation 348.00M 351.00M 216.00M 181.00M 109.00M
Ebit 280.00M 144.00M 340.00M 428.00M 499.00M
Ebitda 628.00M 495.00M 563.00M 579.00M 608.00M
Depreciation and amortization 348.00M 351.00M 223.00M 151.00M 109.00M
Non operating income net other - - - - -
Operating income 302.00M 144.00M 340.00M 428.00M 499.00M
Other operating expenses 4473.00M 4322.00M 3673.00M 3139.00M 2340.00M
Interest expense 61.00M 32.00M 26.00M 28.00M 20.00M
Tax provision 42.00M 16.00M 61.00M 81.00M 96.00M
Interest income 1.00M 1.00M 3.00M - -
Net interest income -60.00000M -31.00000M -23.00000M -31.00000M -23.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 42.00M 16.00M 61.00M 81.00M 96.00M
Total revenue 4775.00M 4444.00M 4013.00M 3567.00M 2820.00M
Total operating expenses 2411.00M 2432.00M 2163.00M 1784.00M 1157.00M
Cost of revenue 2062.00M 1890.00M 1510.00M 1355.00M 1183.00M
Total other income expense net -92.00000M -35.00000M -32.00000M -106.00000M -86.00000M
Discontinued operations - - - - -
Net income from continuing ops 168.00M 93.00M 247.00M 241.00M 317.00M
Net income applicable to common shares - 93.00M 247.00M 241.00M 317.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 6859.00M 7215.00M 5740.00M 4926.00M 4558.00M
Intangible assets 2046.00M 1942.00M 1740.00M 1438.00M 1242.00M
Earning assets - - - - -
Other current assets - 895.00M 796.00M 624.00M 535.00M
Total liab 1466.00M 2954.00M 1788.00M 2554.00M 2376.00M
Total stockholder equity 5393.00M 4261.00M 3952.00M 2372.00M 2182.00M
Deferred long term liab - - - - -
Other current liab 511.00M 482.00M 137.00M 426.00M 264.00M
Common stock 135.00M 129.00M 129.00M 126.00M 126.00M
Capital stock 135.00M 129.00M 129.00M 126.00M 126.00M
Retained earnings 5047.00M 3753.00M 3642.00M 2100.00M 1806.00M
Other liab - 27.00M 48.00M 113.00M 218.00M
Good will 1565.00M 1623.00M 1504.00M 1497.00M 1547.00M
Other assets - 70.00M 42.00M 90.00M 87.00M
Cash 157.00M 187.00M 64.00M 98.00M 120.00M
Cash and equivalents - - - - -
Total current liabilities 942.00M 1161.00M 980.00M 1040.00M 1007.00M
Current deferred revenue - - 416.00M 312.00M 473.00M
Net debt 427.00M 1658.00M 759.00M 1346.00M 1035.00M
Short term debt 72.00M 79.00M 63.00M 43.00M 4.00M
Short long term debt - - - - 13.00M
Short long term debt total 584.00M 1845.00M 823.00M 1444.00M 1155.00M
Other stockholder equity 211.00M 379.00M 181.00M 146.00M 250.00M
Property plant equipment - 1276.00M 846.00M 664.00M 521.00M
Total current assets 2008.00M 2304.00M 1608.00M 1237.00M 1161.00M
Long term investments - - - - -
Net tangible assets - 696.00M 708.00M -563.00000M -607.00000M
Short term investments - - - - -
Net receivables 766.00M 806.00M 732.00M 564.00M 495.00M
Long term debt 0.00000M 1250.00M 550.00M 1249.00M 1050.00M
Inventory 907.00M 1222.00M 748.00M 515.00M 506.00M
Accounts payable 359.00M 600.00M 364.00M 259.00M 266.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 3397.00M
Deferred long term asset charges - - - - -
Non current assets total 4851.00M 4911.00M 4132.00M 3689.00M 3397.00M
Capital lease obligations 584.00M 595.00M 273.00M 195.00M 105.00M
Long term debt total - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments -326.00000M -558.00000M -874.00000M -430.00000M -261.00000M
Change to liabilities - 287.00M 188.00M -55.00000M 254.00M
Total cashflows from investing activities - -558.00000M -874.00000M -430.00000M -261.00000M
Net borrowings - 648.00M -743.00000M 143.00M -158.00000M
Total cash from financing activities -222.00000M 586.00M 512.00M 114.00M -216.00000M
Change to operating activities - -134.00000M -134.00000M -134.00000M -134.00000M
Net income 168.00M -26.00000M 340.00M 428.00M 306.00M
Change in cash -30.00000M 123.00M -34.00000M -22.00000M 57.00M
Begin period cash flow 187.00M 64.00M 98.00M 120.00M 63.00M
End period cash flow 157.00M 187.00M 64.00M 98.00M 120.00M
Total cash from operating activities 518.00M 95.00M 328.00M 295.00M 533.00M
Issuance of capital stock 1091.00M 12.00M 1327.00M 65.00M 40.00M
Depreciation 348.00M 351.00M 216.00M 181.00M 109.00M
Other cashflows from investing activities - - 8.00M 8.00M 8.00M
Dividends paid - -75.00000M -73.00000M -96.00000M 101.00M
Change to inventory 237.00M -402.00000M -222.00000M -51.00000M -102.00000M
Change to account receivables - -19.00000M -163.00000M -97.00000M 18.00M
Sale purchase of stock - - 531.00M 293.00M 67.00M
Other cashflows from financing activities 262.00M 774.00M 1.00M 2.00M 3.00M
Change to netincome - -155.00000M 66.00M 86.00M -59.00000M
Capital expenditures 326.00M 558.00M 584.00M 430.00M 261.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -21.00000M -134.00000M -197.00000M -203.00000M 170.00M
Stock based compensation 17.00M 12.00M 11.00M 19.00M 12.00M
Other non cash items 84.00M -108.00000M -42.00000M -130.00000M -64.00000M
Free cash flow 192.00M -463.00000M -256.00000M -135.00000M 272.00M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AMBBY
Ambu A/S
- -% 18.78 170.00 - 0.81 4.89 0.83 6.40
ABT
Abbott Laboratories
0.98 0.86% 114.38 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation
3.39 0.94% 362.40 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
0.28 0.32% 90.61 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
-0.61 0.72% 83.95 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

Profile

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides anaesthesia, and patient monitoring and diagnostics products. The company offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.

Ambu A/S

Baltorpbakken 13, Ballerup, Denmark, 2750

Key Executives

Name Title Year Born
Ms. Britt Meelby Jensen Chief Exec. Officer 1973
Mr. Thomas Frederik Schmidt Exec. VP & CFO 1971
Mr. Thomas Lykke Henriksen Head of HR Systems 1973
Mr. Henrik Ankjær Exec. VP of Global Operations NA
Mr. Nicolai Thomsen Director of Investor Relations & Strategic Financial Planning NA
Mikkel Trier Wagner Director of Corp. Communications NA
Mr. Bassel Rifai Exec. VP, Chief Marketing Officer & Pres APAC NA
Mr. Anders F. Williamsson Managing Director 1954
Mr. Måns Barsne Exec. VP of Global Innovation & Chief Innovation Officer NA
Mr. Steven R. Block CEO & Pres of USA 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.